Explore ViewRay events, images & videos, press releases and the most up-to-date coverage of MRIdian.
ViewRay In The News
ViewRay, Inc. (Nasdaq: VRAY) today announced preliminary results for the fourth quarter and full fiscal year ended December 31, 2018. The preliminary results have not been audited and are subject to change. Selected Fourth Quarter and Full Year 2018 Preliminary Highlights:
- Recognized 3 revenue units and 1 system upgrade in the fourth quarter of 2018. This resulted in total fourth quarter 2018 revenue of approximately $21 million, compared to fourth quarter 2017 revenue of $19.9 million, primarily from four revenue units.
- Received 8 new orders for MRIdian systems totaling approximately $49 million in the fourth quarter of 2018, compared to orders totaling $34 million in the fourth quarter of 2017.
- Full year 2018 revenue of approximately $81 million, primarily from 13 revenue units and 2 system upgrades, compared to 2017 revenue of approximately $34.0 million, primarily from 6 MRIdian systems.
- Backlog as of December 31, 2018 grew to approximately $212 million.
- Cash and cash equivalents were approximately $167 million as of December 31, 2018.
January 7, 2019
ViewRay, Inc. (Nasdaq: VRAY) announced today the enrollment of the first patient in the Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) Trial, a multi-center, prospective clinical trial for locally advanced or borderline resectable pancreatic cancer. The trial will explore the clinical benefits of precise, high dose radiation therapy enabled by MR-guidance combined with daily on-table adaptation in the treatment of pancreatic cancer. Retrospective analysis of precise, high-dose MR-guided radiation therapy delivered using adaptive dose planning has shown promising results with locally advanced pancreatic cancer, suggesting the potential for improving overall survival relative to patients receiving lower radiation doses, without increasing the rate of serious gastrointestinal toxicity. The compelling nature of the retrospective data prompted the SMART trial, aimed at investigating in a controlled, prospective manner, the robustness of this outcome and tracking quality of life over a 5-year trial period.
January 4, 2019
ViewRay, Inc. (NASDAQ: VRAY) today announced that the Company will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California. Scott Drake, President and CEO, is scheduled to present at 8:30 a.m. Pacific Time on Wednesday, January 9, 2019. An audio webcast of the Company’s presentation will be available on the investor relations section of ViewRay’s website at www.viewray.com. A replay of the webcast will be available for 7 days after the date of the presentation.
December 10, 2018
ViewRay, Inc. announced today the appointment of Robert M. Fuchs as Chief Human Resources Officer effective October 22, 2018. Mr. Fuchs has over 18 years of experience in leading human resources. Prior to joining ViewRay, Rob was the Senior Vice President, Global Human Resources Officer for Advanced Energy. Previously, he served as Senior Vice President, Global Human Resources Officer for Spectranetics. "We are pleased to announce that Rob Fuchs has been named our Chief Human Resources Officer," said Scott Drake, President and CEO. "Attracting, developing, and retaining talent is a top priority for ViewRay. Rob will play an instrumental role in this objective, and his passion for people and performance make him an excellent addition to our company."
November 21, 2018
ViewRay, Inc. (NASDAQ: VRAY) announced today that company management is scheduled to participate in a fireside chat at the 30thAnnual Piper Jaffray Healthcare Conference in New York, NY. Date: Wednesday, November 28, 2018. Time: 12:30 – 12:55 pm ET. Location: Lotte New York Palace. An audio webcast of the Company’s fireside chat will be available on the investor relations section of ViewRay’s website at www.viewray.com. A replay of the webcast will be available for 7 days after the date of the fireside chat
November 16, 2018
ViewRay, Inc. (Nasdaq: VRAY) (“the Company”) today announced financial results for the third quarter ended September 30, 2018. Third Quarter 2018 Highlights:
- Total revenue of $17.7 million, primarily from 3 revenue units.
- Received new orders for MRIdian systems totaling $36.2 million. The backlog as of September 30, 2018 was $200.9 million.
- The Company raised net proceeds of $161.9 million during the quarter from a common stock public offering.
November 8, 2018
ViewRay, Inc. (Nasdaq: VRAY) today announced a collaboration with GenesisCare, the largest provider of cancer services in the UK, Spain and Australia, to introduce the first MRIdian MRI-guided radiotherapy system in the UK to benefit cancer patients. As part of the formal agreement, multiple MRIdian linear accelerators will be deployed within the GenesisCare network, with the first two systems to be installed in the UK. MRIdian leverages the soft-tissue imaging capabilities of MRI to allow oncologists to visualize tumors and personalize treatment more accurately than is possible with conventional technology. The agreement will allow GenesisCare to advance its vision of precision radiation medicine by contributing to the evidence base for, and delivering, high quality image-guided, adaptive radiotherapy.
October 29, 2018
ViewRay, Inc. (Nasdaq: VRAY) today announced highlights from its investor & analyst meeting during the annual meeting of the American Society for Radiation Oncology (ASTRO) in San Antonio, TX. The meeting featured presentations highlighting clinical experiences with the MRIdian System from leading radiation oncologists at the Moffitt Cancer Center and David Geffen School of Medicine at UCLA.
October 22, 2018
ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its third quarter 2018 financial results, which will take place after the market close on Thursday, November 8, 2018. ViewRay will hold a conference call on Thursday November 8, 2018 at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results. The dial-in numbers are (844) 277-1426 for domestic callers and (336) 525-7129 for international callers. The conference ID number is 6190699. A live webcast of the conference call will be available on the investor relations page of ViewRay’s corporate website at www.viewray.com.
October 19, 2018
The company’s MRIdian® and MRIdian Linac – the world’s only FDA-cleared MRI-guided radiation therapy systems – will be featured at the Annual Meeting of the American Society for Radiation Oncology (ASTRO). ASTRO 2018 will be held October 21-24, 2018 in San Antonio, TX and will include a number of presentations highlighting the unique capabilities, clinical experience and patient outcomes.
October 16, 2018
ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will hold a meeting for investors and analysts on Monday, October 22, 2018, (7:00 – 9:00 a.m. CT) during the annual meeting of the American Society for Radiation Oncology (ASTRO) in San Antonio, TX. The meeting will include a brief company update from Scott Drake, President and Chief Executive Officer of ViewRay, followed by presentations from Louis B. Harrison, M.D., FASTRO, Chair and Senior Member, Department of Radiation Oncology at Moffitt Cancer Center and Michael L. Steinberg, M.D., Professor and Chair, Department of Radiation Oncology at the David Geffen School of Medicine at UCLA.
October 9, 2018
ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the appointment of James “Jim” Alecxih as Chief Commercial Officer, effective September 17th, 2018. Mr. Alecxih joins the ViewRay leadership team with extensive experience in commercializing new and innovative devices globally and will be responsible for driving the Company’s commercial expansion.
October 3, 2018
Leading oncology experts from around the world met to discuss the integration of magnetic resonance imaging (MRI) with radiation therapy and its potential to extend life expectancy and reduce common side effects in many cancer patients. ViewRay, Inc. (NASDAQ: VRAY), maker of MRIdian®, the world’s first and only FDA-cleared, MRI-guided radiation therapy system, and Miami Cancer Institute, co-hosted experts from research hospitals at the cutting-edge of cancer treatment at the September 28 symposium and panel discussion.
October 1, 2018
ViewRay, Inc. (NASDAQ: VRAY) announced today that members of the executive management team are scheduled to present at the Cantor Global Healthcare Conference in New York, NY on Tuesday, October 2, 2018. An audio webcast of the Company’s presentation will be available on the investor relations section of ViewRay’s website at www.viewray.com. A replay of the webcast will be available for 7 days after the date of the presentation.
September 25, 2018
ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced grants of stock options and restricted stock units to several new officers and employees. These awards were granted as inducements material to entering into employment with ViewRay, in accordance with Nasdaq Listing Rule 5635(c)(4) and as approved by the Compensation Committee of ViewRay’s Board of Directors.
September 17, 2018
ViewRay, Inc. (Nasdaq: VRAY) announced today that Acibadem Maslak Hospital in Istanbul, Turkey has begun treating patients with ViewRay’s MRIdian® Linac, the world’s first system to combine MRI guidance and linear accelerator radiation delivery. These treatments mark the first in Turkey using MRI-guided radiation therapy.
September 13, 2018
ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients,today announced the pricing of an underwritten public offering of 16,216,217 shares of common stock at a price to the public of $9.25 per share, for gross proceeds of $150 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ViewRay. All of the shares to be sold in the offering will be offered by ViewRay. In addition, ViewRay has granted the underwriters of the offering a 30-day option to purchase up to an additional 2,432,432 shares of common stock at the public offering price, less underwriting discounts and commissions.
August 15, 2018
ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced that it has commenced an underwritten public offering of $125.0million of shares of its common stock. In addition, ViewRay expects to grant the underwriters a 30-day option to purchase up to an additional $18.75million of shares of its common stock at the public offering price, less the underwriting discounts and commissions. All of the shares of common stock to be sold in the offering will be offered by ViewRay. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
August 14, 2018
ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the second quarter ended June 30, 2018. Total revenue for the second quarter ended June 30, 2018 was $16.4 million, compared to $0.7 million for the same period last year. Revenue for the second quarter ended June 30, 2018 included 3 new MRIdian system installs or delivery, all recognized as product revenue.
August 3, 2018
ViewRay, Inc. (Nasdaq: VRAY), makers of the world’s only FDA-cleared MRI-guided radiation therapy system, announced today that the company’s MRIdian® System is the focus of 55 abstracts selected by the American Association of Physicists in Medicine (AAPM) for presentation during their 2018 Annual Meeting. AAPM is the largest association of medical physicists in the world, and this year’s meeting will be held July 29-August 2 in Nashville.
July 26, 2018
ViewRay Appoints Scott Drake as President, Chief Executive Officer and a Member of the Board of Directors, Shar Matin as Chief Operating Officer, and D. Keith Grossman as a Member of the Board of Directors
ViewRay, Inc. (Nasdaq: VRAY), maker of the market-leading MRI-guided radiation therapy system, announced today the appointment of medical device industry veterans Scott Drake as its President and Chief Executive Officer and Shar Matin as its Chief Operating Officer, effective immediately. In connection with his appointment, Mr. Drake has also been appointed to the ViewRay Board of Directors. In addition, ViewRay announced the appointment of D. Keith Grossman to the ViewRay Board of Directors. ViewRay Pre-Releases Preliminary Second Quarter 2018 Revenue of $16 Million and Reaffirms Revenue Guidance of $80 to $90 Million for 2018
July 25, 2018
Oncology professionals: Interested in learning how clinics have integrated MRI-Guided RT into their practice? Watch the July 26th Webinar and hear from clinicians in Amsterdam and St. Louis, MO who, for several years, have been using real-time image guidance and on-table plan adaptation on the MRIdian® system. Webinar: ow.ly/AdFN30kVafc
July 23, 2018
ViewRay, Inc. (Nasdaq: VRAY) announced that the company’s MRIdian® Linac has been selected for installation at Centre Georges-François Leclerc (CGFL) in Dijon, France as part of a tender award contract with UNICANCER, a hospital network of 19 French Comprehensive Cancer Centers (FCCCs).
July 11, 2018
ViewRay, Inc. (Nasdaq: VRAY)announced today that Palos Health, in partnership with Loyola Medicine, has installed ViewRay’s MRIdian® Linac System for MR image-guided radiation therapy at its Palos Health South Campus in Orland Park, Illinois. Palos Health becomes the first community hospital in the United States, and the only center in Illinois with the company’s next generation linear accelerator-based system.
July 9, 2018
The symposium, titled “Advanced Applications of MR-Guided Radiotherapy Symposium,” brought together nearly 200 members of the global oncology community, including radiation oncologists and medical physicists, for talks on various aspects of MR image-guided radiation therapy presented by five experts in the field.
June 21, 2018
University of Wisconsin Carbone Cancer Center in Madison, Wisconsin, has begun patient treatments with the company’s MRIdian® Linac, following an upgrade of the hospital’s original MRIdian System. The next-generation MRIdian Linac combines the benefits of MR-image guidance with linear accelerator radiation delivery for the precision treatment of cancer.
June 21, 2018
The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, Missouri, is treating patients with the company’s second-generation MR image-guided radiotherapy system, the MRIdian® Linac. Siteman is the first U.S. cancer center to offer cancer therapy with both MRIdian and MRIdian Linac, furthering its leadership role in MR image-guided radiation therapy.
June 13, 2018
ViewRay’s Chris Raanes on Bloomberg-Radio
Listen to the Bloomberg-Radio segment
June 11, 2018
Experts in MR image-guided radiation therapy will share their experiences during an educational symposium to be held on Friday, September 28, 2018 in Miami. The event aims to facilitate clinical and scientific discovery, as well as educate clinicians interested in the novel advancements of MR image-guided radiation therapy for treating cancer.
May 23, 2018
ViewRay, Inc. (Nasdaq: VRAY) announced today that members of its Clinical Cooperative Think Tank (C2T2) gathered last week in Barcelona, Spain to discuss data from the nearly 3,000 patients treated using ViewRay’s MRIdian MR image-guided radiotherapy system. The group also evaluated new clinical opportunities and potential future trials for this novel technology.
May 2, 2018
ViewRay, Inc. (Nasdaq: VRAY) announced today an order for the company’s MRIdian® MR image-guided linac at the University Hospital Zurich (USZ) in Zurich, Switzerland. The order formalizes the previously announced tender award from the Swiss National R’Equip programme. Once commissioned, the USZ MRIdian system will be the first in Switzerland, and among the first MR-guided linac systems in Europe to treat patients.
March 14, 2018
The Henry Ford Cancer Institute is the first in the world to offer patients an advanced radiation therapy that uses an FDA-approved real-time magnetic resonance imaging (MRI) to deliver more precise and accurate radiation treatment using a linear accelerator. With this new system, called ViewRay MRIdian Linac®, it is now possible to image the treatment area and deliver radiation at the same time -- more effectively protecting surrounding healthy tissue. Watch the Spotlight on Innovation: MRI-Guided Radiation Therapy segment.
November 1, 2017
Competition Seeks to Document MR-Guided Radiotherapy Clinical Applications and Experiences to Increase Information Sharing and Help Improve Cancer Care The Cureus Journal of Medical Science announced today the start of a medical case report publishing competition aimed at advancing the clinical practice of MR-guided radiation therapy by documenting clinical applications and experience and sharing the information freely with the oncology community...All eligible submissions will undergo an independent pre-publication peer review conducted by a world-class team of radiation oncology and medical physics experts; and, three monetary prizes will be awarded to the published articles that receive the highest Cureus SIQ rating. Click the title to view the complete press release from The Cureus Journal of Medicine.
September 28, 2017
The company's MRIdian and MRIdian Linac systems will be featured at the Annual Meeting of the American Society for Radiation Oncology (ASTRO), with a number of presentations highlighting clinical experience and patient outcomes. The ASTRO meeting will be held September 24-27, 2017 in San Diego. MR-guided radiation therapy remains a significant area of interest, as reflected by the 21 MRIdian clinical presentations and posters accepted as part of ASTRO's Scientific Sessions.
September 21, 2017
Bringing the benefits of soft-tissue visualization and adaptive therapy to cancer patients throughout France. http://france3-regions.francetvinfo.fr/occitanie/herault/montpellier/radiotherapie-irm-embarquee-cibler-tumeurs-montpellier-fin-2018-1328773.html
September 16, 2017
Miami Cancer Institute, part of Baptist Health South Florida, announced today that it will acquire ViewRay’s MRIdian Linac System, the world’s first and only FDA-cleared MRI-guided radiation therapy system. The MRIdian system will be part of the healthcare organization’s new Miami Cancer Institute, a multidisciplinary, destination cancer center and member of the Memorial Sloan Kettering Cancer Alliance. The MRIdian treatments are expected to be available for patient care in spring 2018.
July 27, 2017
The Henry Ford Cancer Institute has treated the world’s first cancer patient today with an advanced radiation therapy that uses an FDA-cleared real-time magnetic resonance imaging and linear accelerator delivery for more precise and accurate radiation treatment.
July 19, 2017
The new Orlando Health UF Health Cancer Center – Ocoee in Health Central hospital will use Central Florida's latest cancer-tracking technology called MRIdian.
The cutting-edge technology provides a combination of simultaneous radiation therapy and magnetic resonance imaging (MRI) for cancer treatment.
June 28, 2017
Moffitt Cancer Center recently signed a deal to acquire ViewRay’s MRIdian Linac System, the world’s first and only FDA-cleared MRI-guided radiation therapy system, to assist with precision radiation. MRIdian Linac provides a unique combination of simultaneous radiation therapy delivery and continuous magnetic resonance imaging (MRI) for the treatment of cancer.
June 27, 2017
The first MRI-guided radiation treatment took place in January 2014, at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine. The treatment was performed using ViewRay's MRIdian, which integrates a 0.35 T MRI with three gamma-emitting cobalt-60 sources. We report on more than 2 years of clinical experience in treating patients with the world's first MR-IGRT system.
June 1, 2017
February 1, 2017
Doctors say a medical breakthrough in radiation delivery is ensuring they hit their tumor targets. It also means less toxicity to the surrounding healthy tissue. Here are more details on this high-tech tool that is helping doctors battle cancer at Sylvester Comprehensive Cancer Center in Miami, Florida.
September 26, 2016
August 1, 2016
In this video interview, Mr. Raanes and our host discuss the following topics: Overview of ViewRay, Inc., Describes the company’s medical device, MRIdian®, Where the technology comes from and currently treating patients, Explains the process for approval process, and where they have been approved, Discusses various indications for the company’s device, Reimbursement, Mr. Raanes’ background, Growth drivers for ViewRay, Inc.
December 15, 2015
With the first MRI-guided radiotherapy system in the western U.S.— and one of only three locations in the world — UCLA radiation oncologists have an unparalleled ability to see and accurately target cancerous tumors, while making real-time adjustments to treatment delivery. Beverly Hills Courier, November 2014
November 14, 2014
Precise adaptive radiation therapy guided by real-time MRI images could prove a significant advance in radiation oncology. Integrating those two tools is the driving force behind the MRIdian system, a combined real-time MRI and radiation therapy delivery process developed by Cleveland-based ViewRay. Radiology Today, September 2014, Vol. 15 No. 9 P. 20
September 1, 2014
A new technology called MRI-guided radiation therapy allows tumors to be visualized in real-time during treatment. In what has been called “a world’s first,” physicians at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis began treating patients with this new therapy in January 2014. Radiation Oncology News for Administrators, June 2014 This article was originally published in Volume 24 No 2 of "Radiation Oncology News for Administrators" © 2014 The Society for Radiation Oncology Administrators (www.sroa.org). The Society for Radiation Oncology Administrators, the authority for radiation oncology operations, provides education, advocacy and information to radiation oncology administrators.
June 1, 2014
The ViewRay system, a MRI-guided radiation therapy system, is being used to treat patients at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, Mo. The ViewRay system provides a combination of simultaneous radiation therapy delivery and continuous magnetic resonance imaging (MRI) for the treatment of cancer. Imaging Technology News, February 2014
February 10, 2014
The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, Missouri has started to treat patients using the ViewRayTM system, the world’s first and only real-time MRI-guided radiation therapy system. The Advisory Board, February 2014
February 7, 2014
Cancer patients are receiving a significant boost in their treatment options as ViewRay’s (Cleveland) MRI-guided radiation therapy system is being used to treat patients at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine (St. Louis). Medical Device Daily, February 2014
February 1, 2014
The collimators in the MRI-guided radiotherapy system require multiple components to shape gamma ray radiation therapy beams, and each has to be precisely controlled by one interlinked motion control system. Medical Design, March 2013
March 11, 2013
ViewRay's president believes the company's MRI machines will revolutionize radiation therapy. "I think this will change the way radiation oncology is practiced,” says Chris Raanes, ViewRay president and CEO. “Because once you've got the ability to see what you are doing in real time, how could you ever go back?” Crain's Cleveland Business, March 2013
March 4, 2013
By using real-time MRI, the ViewRay system shows soft tissue as it is being treated and adjusts for its movement in real time, without using any additional radiation. medGadget, May 2012
May 31, 2012
ViewRay is well capitalized for its product launch, says CFO David Chandler, noting that the company has raised $45 million since 2010. Crain's Cleveland Business, March 2012
March 13, 2012